Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.005
+0.005 (+0.53%)
Streaming Delayed Price
Updated: 11:57 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
Next >
OKYO Pharma Announces Public Offering of Ordinary Shares
September 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
September 08, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
August 29, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
August 15, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Announces Withdrawal of Public Offering
July 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
July 27, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
June 06, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
May 11, 2023
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform
From
OKYO Pharma LTD
Via
GlobeNewswire
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
May 09, 2023
Via
ACCESSWIRE
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
April 25, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Via
ACCESSWIRE
Notice of General Meeting and Publication of Circular
April 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Notice of Intention to Delist From The London Stock Exchange
April 04, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 30, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 29, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
OKYO Pharma Announces PDMR Dealing
March 24, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
March 16, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
March 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
March 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
March 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.